Akari Therapeutics Plc (AKTX)

Business Summary

Akari Therapeutics, Plc is an oncology company focused on developing next-generation antibody-drug conjugates (ADCs) built around novel, proprietary payloads to treat cancer ¹. The company's core business model revolves around the discovery and development of these ADCs, with a primary focus on advancing its lead candidate, AKTX-101, towards clinical trials. Revenue generation is currently absent, as the company has not commercialized any products to date and expects to incur significant losses for the foreseeable future ². The business model is largely dependent on successful preclinical and clinical development, regulatory approvals, and potential collaborations or strategic partnerships for commercialization ³.

The company's lead payload, PH1, targets RNA splicing by modulating the spliceosome, a mechanism distinct from the two standard payload classes (microtubule inhibitors and DNA-damaging agents like topoisomerase I inhibitors) that comprise over 90% of ADCs in late-stage clinical development ⁴. PH1's disruption of RNA splicing offers a dual mode of action: direct cell killing and cytotoxicity, and the generation of neoantigen proteins that activate both the innate and adaptive immune systems ⁵. Preclinical studies have shown PH1 to be active against various cancers, including urothelial cancers with FGFR3-fusions, lung cancers with SMARCA4 deletions and BRAF G466V mutations, and K-Ras G12V driven pancreatic cancers, as well as metastatic prostate cancer cells driven by AR-v7 and AR-hormone dependent prostate cancer ⁶.

Akari's lead product candidate, AKTX-101, is a preclinical Trop-2-targeting ADC that combines the PH1 payload with a proprietary non-cleavable linker ⁷. Trop-2 is an antigen expressed in several solid tumors, including lung, breast, bladder, gastric, head and neck, and pancreatic cancers ⁸. Preclinical studies indicate AKTX-101 has significant activity and prolonged survival in animal models compared to ADCs with traditional payloads, and it has the potential for synergistic effects with checkpoint inhibitors due to PH1's unique neoantigen generation ⁹. The company is also developing AKTX-102, an ADC targeting the CEACAM5 antigen, which is relevant in pancreatic, colon, stomach, esophageal, and lung cancers ¹⁰.

For the fiscal year ended December 31, 2025, Akari Therapeutics reported a net loss applicable to common shareholders of $17.3 million ¹¹, an improvement from the $19.8 million net loss in 2024 ¹². The loss from operations for 2025 was $17.3 million, a 20% decrease from $21.6 million in 2024 ¹³. Research and development expenses decreased by approximately $4.2 million, or 60%, to $2.815 million in 2025 from $6.983 million in 2024 ¹⁴. General and administrative expenses decreased by $0.4 million, or 4%, to $9.280 million in 2025 from $9.664 million in 2024 ¹⁵. The company recognized an impairment loss on other intangible assets of $5.180 million in 2025, compared to none in 2024 ¹⁶. Merger-related expenses and restructuring and other expenses, which were $3.273 million and $1.723 million respectively in 2024, were zero in 2025 ¹⁷. Interest income was less than $0.1 million in both 2025 and 2024 ¹⁸. A gain on settlement of current liabilities of approximately $3.0 million was recognized in 2025, with no such gain in 2024 ¹⁹. A non-cash loss on debt extinguishment of $3.2 million was recognized in 2025, compared to none in 2024 ²⁰. The change in fair value of warrant liabilities resulted in a non-cash revaluation gain of approximately $0.8 million in 2025, down from $2.1 million in 2024 ²¹. Net foreign currency exchange resulted in a loss of approximately $0.4 million in 2025, compared to a gain of less than $0.1 million in 2024 ²². As of December 31, 2025, the company had cash of approximately $5.2 million ²³ and an accumulated deficit of $264.5 million ²⁴.

The year-over-year comparison shows a significant decrease in operating losses, primarily driven by the absence of merger-related and restructuring expenses in 2025, which were substantial in 2024. Research and development expenses also saw a considerable reduction, mainly due to the suspension of legacy programs (HSCT-TMA clinical development and PAS-nomacopan preclinical program) and a strategic shift to focus resources on the ADC platform ²⁵. This reprioritization led to an impairment loss on the PHP-303 in-process R&D asset in 2025 ²⁶. While general and administrative expenses slightly decreased, non-cash stock-based compensation within this category increased by $1.1 million ²⁷. The company also engaged in multiple financing activities in 2025, including equity offerings and note issuances, which provided net proceeds and reduced outstanding debt ²⁸.

Significant operational developments during the period include the strategic prioritization of the ADC platform and programs, with a focus on advancing AKTX-101. The company initiated GMP manufacturing activities for AKTX-101 in December 2025, partnering with WuXi Biologics/XDC, to support its goal of starting a First-In-Human Phase 1 trial by late 2026/early 2027 ²⁹. Scientific disclosures at the 2025 Society for Immunotherapy of Cancer Annual Meeting highlighted PH1's novel immune mechanism-of-action data, showing potential for synergistic effects with checkpoint inhibitors ³⁰. The company also expanded its intellectual property portfolio with three new provisional patent applications in 2025, covering oncogenic drivers, immunogenic payloads, and synergy with checkpoint inhibitors, with anticipated expiry between September and October 2045 ³¹. Leadership updates included the appointment of Abizer Gaslightwala as President and Chief Executive Officer in April 2025 and Kameel Farag as Interim Chief Financial Officer in October 2025 ³².

Business Outlook & Financial Sufficiency

Management's near-term operational strategy is focused on advancing AKTX-101 into IND-enabling activities and clinical readiness, with a projected timeline to advance AKTX-101 into clinical trials by the first quarter of 2027 ³³. The company also aims to maintain the ability to expand its PH1-based ADC pipeline as capital and priorities permit ³⁴.

A major growth area for Akari Therapeutics is the development of its novel PH1 payload and the resulting ADC candidates. PH1's unique dual mode of action, combining cytotoxicity with immune system activation through neoantigen formation, is expected to offer more effective cancer-killing properties, robust immune system activation, synergy with checkpoint inhibitors, reduced tumor resistance, and improved safety and tolerability compared to existing ADCs ³⁵. The company plans to leverage this novel payload to generate a pipeline of ADC candidates targeting different cancer antigens, such as AKTX-101 (Trop-2) and AKTX-102 (CEACAM5) ³⁶. The anticipated expiry of the patent family covering next-generation Thailanstatin diastereomer payloads, novel Trop-2 antibodies, and Trop-2 ADCs, including AKTX-101, is April 2043 ³⁷. Additionally, three provisional patent applications filed in 2025, covering targeting oncogenic drivers, spliceosome modulators as immunogenic payloads, and synergy with checkpoint inhibitors, are anticipated to expire between September and October 2045, providing broad protection over ADC molecules using splicing modulation ³⁸.

Another growth vector involves strategic partnerships. Akari intends to leverage its ADC product candidates and novel PH1 payload to partner with biopharmaceutical companies interested in developing immuno-oncology ADCs ³⁹. This flexible partnering strategy allows for out-licensing rights to specific ADCs like AKTX-101 or licensing rights to the PH1 payload for partners to develop their own proprietary ADC candidates ⁴⁰. The company has suspended further internal development of its legacy programs (nomacopan, PAS-nomacopan, and PHP-303) and intends to seek external partners for their continued development ⁴¹.

Operationally, the company has initiated GMP manufacturing activities for AKTX-101 in December 2025, partnering with WuXi Biologics/XDC, to ensure a high-quality and reliable virtual manufacturing model for clinical-grade supply ⁴². This supports the planned Phase 1 first-in-human study timeline. The company's strategy also involves defining a tumor strategy for AKTX-101 that drives the fastest and most efficient development and approval while maximizing future commercial opportunity ⁴³.

Regarding capital allocation, Akari Therapeutics expects its existing cash of $5.2 million as of December 31, 2025, to be sufficient to fund operations into April 2026 ⁴⁴. The company will require additional capital to fund future operations and service obligations ⁴⁵. It plans to seek additional funding through debt or equity financings, credit facilities, or out-licensing arrangements of its product candidates ⁴⁶. The company has an equity line of credit (ELOC) with White Lion Capital, LLC, providing the right to require White Lion to purchase up to $25,000,000 of newly issued ordinary shares, subject to certain limitations and conditions, including the effectiveness of a registration statement ⁴⁷.

Management explicitly flagged several structural headwinds and execution risks. The company has a history of operating losses and does not expect to generate revenue or profitability in the short term, requiring substantial additional capital ⁴⁸. There is no assurance that additional funds will be available on acceptable terms or at all, which could lead to delays or termination of product candidate development ⁴⁹. The proprietary ADC Platform is based on novel, unproven technologies, and there is no guarantee that it will result in approvable or marketable products, exposing the company to unforeseen risks and making it difficult to predict development time and cost ⁵⁰. Preclinical and clinical drug development is a lengthy, expensive, and uncertain process, with potential for delays in commencement, enrollment, or completion of trials, or failure to demonstrate safety and efficacy ⁵¹. Serious adverse events or undesirable side effects identified during development or after approval could lead to discontinuation of programs or revocation of marketing authorizations ⁵². The company relies on third parties for preclinical studies, clinical trials, and manufacturing, and unsatisfactory performance by these third parties could harm the business ⁵³. The biotechnology industry is highly competitive, and product candidates may become obsolete ⁵⁴. The company currently has limited sales, marketing, and distribution capabilities, and failure to establish these, either independently or through collaborations, could hinder commercialization ⁵⁵. Obtaining adequate third-party payor coverage and reimbursement for newly approved products is uncertain, and failure to do so could limit marketability and revenue generation ⁵⁶.

Management Sentiments & Priorities

Management's message to shareholders emphasizes a strategic pivot towards its novel ADC platform, anchored by the PH1 payload, and the advancement of its lead program, AKTX-101, towards clinical readiness. The company is prioritizing IND-enabling activities for AKTX-101 with a goal of initiating a First-In-Human Phase 1 trial by late 2026/early 2027 ⁶⁸. This includes coordinated execution of GMP product supply, for which WuXi Biologics/XDC has been selected as a partner, and non-clinical data package workstreams ⁶⁹. Management also highlights the unique immuno-oncology mechanism of PH1, which has shown potential for synergistic effects with checkpoint inhibitors in preclinical studies, and the expansion of its intellectual property portfolio to protect these novel mechanisms and combination strategies ⁷⁰. Despite a history of operating losses and the need for additional capital, management is actively pursuing financing and liquidity initiatives, including equity offerings and an equity line of credit, to fund future operations ⁷¹. The company's strategic priorities include advancing AKTX-101, leveraging its ADC candidates and PH1 payload for partnerships with biopharmaceutical companies, and continuing to progress AKTX-102, a discovery-stage CEACAM5-directed ADC ⁷².

Risk Factors

The company faces material risks including its history of operating losses and the need for substantial additional capital, with no assurance of timely or acceptable funding, which could lead to delays or termination of product development and raises substantial doubt about its ability to continue as a going concern ⁵⁷. Material weaknesses in internal control over financial reporting have been identified, and if remediation efforts are ineffective, it could adversely affect investor confidence and the value of ADSs ⁵⁸. The proprietary ADC Platform is based on novel, unproven technologies, exposing the company to unforeseen risks and making it difficult to predict development time and cost, with no guarantee of approvable or marketable products ⁵⁹. Preclinical and clinical drug development is lengthy, expensive, and uncertain, with potential for substantial delays or failure to demonstrate safety and efficacy, which could prevent commercialization ⁶⁰. Serious adverse events or undesirable side effects identified during development or after approval could lead to discontinuation of programs, refusal of regulatory approval, or revocation of marketing authorizations ⁶¹. The company relies heavily on third parties for preclinical studies, clinical trials, and manufacturing, and unsatisfactory performance by these third parties could harm the business ⁶². The biotechnology industry is highly competitive, and product candidates may become obsolete due to rapid technological evolution and better-funded competitors ⁶³. Cybersecurity threats, including attacks by hackers or employee error, could compromise sensitive data, disrupt operations, and lead to legal claims or significant regulatory penalties ⁶⁴. Geopolitical instability, such as the March 2026 conflict in Iran involving the United States and Israel, and high inflation, could materially adversely affect the global economy, capital markets, and the company's business, financial condition, and results of operations ⁶⁵. Disruptions at regulatory agencies like the FDA and SEC due to funding shortages or political events could delay product review and approval ⁶⁶. The company's ability to use net operating losses to offset future income may be limited by ownership changes under Section 382 of the Internal Revenue Code ⁶⁷.

View Source Annual Report on SEC.gov ↗

References

[1] Item 1, Business — Overview
[2] Item 7, MD&A — Financial Condition, Liquidity and Capital Resources
[3] Item 1A, Risk Factors — Risks Related to Our Financial Position and Our Capital Requirements
[4] Item 1, Business — Background
[5] Item 1, Business — Our Novel Payload
[6] Item 1, Business — Overview
[7] Item 1, Business — AKTX-101: Our Lead ADC Product Candidate
[8] Item 1, Business — AKTX-101: Our Lead ADC Product Candidate
[9] Item 1, Business — AKTX-101: Our Lead ADC Product Candidate
[10] Item 1, Business — Overview
[11] Item 7, MD&A — Net Loss Applicable to Common Shareholders
[12] Item 7, MD&A — Net Loss Applicable to Common Shareholders
[13] Item 7, MD&A — Comparison of the Years Ended December 31, 2025 and 2024
[14] Item 7, MD&A — Research and development expenses
[15] Item 7, MD&A — General and administrative expenses
[16] Item 7, MD&A — Impairment loss
[17] Item 7, MD&A — Merger-related expenses
[18] Item 7, MD&A — Interest income
[19] Item 7, MD&A — Gain on settlement of current liabilities
[20] Item 7, MD&A — Loss on debt extinguishment
[21] Item 7, MD&A — Change in fair value of warrant liabilities
[22] Item 7, MD&A — Foreign currency exchange gain, net
[23] Item 7, MD&A — Financial Condition, Liquidity and Capital Resources
[24] Item 7, MD&A — Financial Condition, Liquidity and Capital Resources
[25] Item 7, MD&A — Operating Activities
[26] Item 7, MD&A — Impairment Assessment of Goodwill and Other Intangible Assets
[27] Item 7, MD&A — General and administrative expenses
[28] Item 7, MD&A — Financing Activities
[29] Item 7, MD&A — AKTX-101 IND-Enabling Plan and Activities
[30] Item 7, MD&A — Scientific Disclosures – 2025 SITC Annual Meeting
[31] Item 7, MD&A — Intellectual Property – Expanding Protection Around PH1, Immune Activation, and Combination Strategies
[32] Item 7, MD&A — Leadership Updates
[33] Item 7, MD&A — AKTX-101 IND-Enabling Plan and Activities
[34] Item 7, MD&A — Overview
[35] Item 7, MD&A — Overview
[36] Item 7, MD&A — Overview
[37] Item 7, MD&A — Intellectual Property – Expanding Protection Around PH1, Immune Activation, and Combination Strategies
[38] Item 7, MD&A — Intellectual Property – Expanding Protection Around PH1, Immune Activation, and Combination Strategies
[39] Item 1, Business — Our Strategy
[40] Item 1, Business — Our Strategy
[41] Item 7, MD&A — Overview
[42] Item 7, MD&A — AKTX-101 IND-Enabling Plan and Activities
[43] Item 1, Business — Our Strategy
[44] Item 7, MD&A — Funding Requirements
[45] Item 7, MD&A — Funding Requirements
[46] Item 7, MD&A — Funding Requirements
[47] Item 7, MD&A — White Lion Ordinary Share Purchase and Registration Rights Agreements
[48] Item 1A, Risk Factors — We have a history of operating losses and cannot give assurance of future revenues or operating profits.
[49] Item 1A, Risk Factors — We will require substantial additional capital to fund our operations, and if we are unable to obtain such capital, we will be unable to successfully develop and commercialize any product candidates.
[50] Item 1A, Risk Factors — Our proprietary ADC Platform is based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval, and we may not be successful in our efforts to expand our development portfolio of product candidates.
[51] Item 1A, Risk Factors — Preclinical and clinical drug development is a lengthy and expensive process, with uncertain timelines and outcomes. If preclinical studies or clinical trials of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals and therefore be unable to commercialize our product candidates or any of our future product candidates on a timely basis or at all.
[52] Item 1A, Risk Factors — Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval, which could lead to the discontinuation of our development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates, any of which would limit the commercial potential of such product candidates.
[53] Item 1A, Risk Factors — We rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner it may harm our business.
[54] Item 1A, Risk Factors — Our industry is highly competitive, and our product candidates may become obsolete.
[55] Item 1A, Risk Factors — If we are unable to establish sales, marketing and distribution capabilities on our own or through collaborations with partners, we may not be successful in commercializing any approved drugs.
[56] Item 1A, Risk Factors — Even if we are able to commercialize any product candidate, the third-party payor coverage and reimbursement status of newly approved products is uncertain. Failure to obtain or maintain adequate coverage and reimbursement for our product candidates could limit our ability to market those products and decrease our ability to generate revenue.
[57] Item 1A, Risk Factors — We have a history of operating losses and cannot give assurance of future revenues or operating profits.
[58] Item 1A, Risk Factors — We have identified material weaknesses in our internal control over financial reporting. If our remediation of the material weaknesses are not effective, or if we experience additional material weaknesses in the future or otherwise fail to maintain an effective system of internal controls in the future, we may not be able to accurately or timely report our financial condition or results of operations, which may adversely affect investor confidence in us and, as a result, the value of our ADSs.
[59] Item 1A, Risk Factors — Our proprietary ADC Platform is based on novel technologies that are unproven and may not result in approvable or marketable products, which exposes us to unforeseen risks and makes it difficult for us to predict the time and cost of product development and potential for regulatory approval, and we may not be successful in our efforts to expand our development portfolio of product candidates.
[60] Item 1A, Risk Factors — Preclinical and clinical drug development is a lengthy and expensive process, with uncertain timelines and outcomes. If preclinical studies or clinical trials of our product candidates are prolonged or delayed, we may be unable to obtain required regulatory approvals and therefore be unable to commercialize our product candidates or any of our future product candidates on a timely basis or at all.
[61] Item 1A, Risk Factors — Serious adverse events, undesirable side effects or other unexpected properties of our product candidates may be identified during development or after approval, which could lead to the discontinuation of our development programs, refusal by regulatory authorities to approve our product candidates or, if discovered following marketing approval, revocation of marketing authorizations or limitations on the use of our product candidates, any of which would limit the commercial potential of such product candidates.
[62] Item 1A, Risk Factors — We rely on third parties to conduct, supervise and monitor our preclinical studies and clinical trials, and if those third parties perform in an unsatisfactory manner it may harm our business.
[63] Item 1A, Risk Factors — Our industry is highly competitive, and our product candidates may become obsolete.
[64] Item 1A, Risk Factors — Our proprietary information may be lost or we may suffer security breaches.
[65] Item 1A, Risk Factors — We are currently operating in a period of economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability. Our business, financial condition and results of operations could be materially adversely affected by any negative impact on the global economy and capital markets resulting from the geopolitical tensions or high inflation.
[66] Item 1A, Risk Factors — Disruptions at the FDA, the SEC and other government agencies caused by the change in presidential administration, funding shortages or potential funding shortages could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner, or otherwise prevent those agencies from performing normal business functions, which could negatively impact our business and our timelines.
[67] Item 1A, Risk Factors — Our ability to use net operating losses to offset future income may be subject to certain limitations.
[68] Item 7, MD&A — AKTX-101 IND-Enabling Plan and Activities
[69] Item 7, MD&A — AKTX-101 IND-Enabling Plan and Activities
[70] Item 7, MD&A — Scientific Disclosures – 2025 SITC Annual Meeting
[71] Item 7, MD&A — Financing and Liquidity Initiatives
[72] Item 1, Business — Our Strategy

Analysis on 5/19/2026

Recent Material Events

Aug 13, 2026Material Event

Akari Therapeutics reported second quarter 2026 financial results and highlighted operational progress. The company raised approximately $8.6 million in gross proceeds through a private placement of $5.5 million and warrant exercises worth $3.1 million, resulting in net proceeds of approximately $8.0 million. Research and development expenses increased to $2.1 million from $0.7 million in the prior year period, while general and administrative expenses remained stable at $2.5 million. The company reported a net loss of $4.8 million compared to $1.9 million previously. Cash reserves stood at $7.7 million as of June 30, 2026. Akari Therapeutics is an oncology biotechnology company developing antibody drug conjugates with a novel RNA splicing-targeting payload.

Jul 2, 2026Material Event

At its Annual General Meeting on June 30, 2026, Akari Therapeutics, Plc shareholders failed to re-elect James Neal to the Board of Directors, ending his service as a director and his roles as Audit Committee member and Compensation Committee Chair. Consequently, the Board appointed Dr. Ray Prudo to the Audit Committee and Robert Bazemore as Chair of the Compensation Committee. Shareholders approved the issuance of ordinary shares under the ELOC Purchase Agreement, the issuance of Series H, I, and J Warrants for up to 4,411,764 ADSs, and a potential private placement resulting in a change of control. The company also authorized directors to allot shares up to a nominal amount of $20,000 through June 30, 2031. Akari Therapeutics is a biopharmaceutical company that develops therapies for inflammatory and immune-mediated diseases.

Jun 26, 2026Material Event

Akari Therapeutics, Plc amended its existing securities purchase agreement to consolidate the second and third tranches of a private placement into a single closing. The original agreement involved the sale of 1,470,588 American Depository Shares (ADSs) or prefunded warrants, plus Series H, I, and J warrants. Following the first closing on May 27, 2026, the amendment rescheduled the remaining two tranches to a combined closing on June 26, 2026, where the company issued the remaining 980,395 ADSs or prefunded warrants. Issuance of the Series Warrants remains contingent upon shareholder approval at the June 30, 2026, annual general meeting. Akari Therapeutics is a biopharmaceutical company.